Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): Stability of a monoclonal antibody

Journal of Pharmaceutical Sciences

Volumn 96, Issue 8, 2007, Pages 1983-2008

  Abdul Fattah, Ahmad M ^a   Truong Le, Vu ^b   Yee, Luisa ^b   Nguyen, Lauren ^b   Kalonia, Devendra S ^a   Cicerone, Marcus T ^c   Pikal, Michael J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b MEDIMMUNE   (United States)

^c NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

Author keywords

Composition heterogeneity; Electron spectroscopy for chemical analysis; Glass dynamics; Incoherent elastic neutron scattering; Molecular mobility; Protein secondary structure; Protein stabilization; Specific surface area; Structural relaxation time

Indexed keywords

IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; SUCROSE;

ARTICLE; CHEMICAL ANALYSIS; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; FREEZE DRYING; GLASS TRANSITION TEMPERATURE; INFRARED SPECTROSCOPY; ISOTHERMAL TITRATION CALORIMETRY; MOISTURE; NEUTRON SCATTERING; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; SCANNING ELECTRON MICROSCOPE; SOLID STATE; SPRAY DRYING; THERMAL ANALYSIS;

EID: 33947287573     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20859     Document Type: Article

References (79)

1. Carpenter JF, Pikal MJ, Randolph TW. 1997. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm Res 14: 969-975.
2. Rational Design of Stable Protein Formulations: Theory and Practice. 2002. In: Carpenter JF, Manning MC, editors. Pharmaceutical Biotechnology, vol. 13. New York, NY: Kluwer/Plenum. 203p.
3. Lyophilization of Biopharmaceuticals. 2004. In Costantino HR, Pikal MJ, editors. Biotechnology: Pharmaceutical Aspects, vol. 2. Arlington, VA: AAPS Press. 686p.
4. Maa Y-F, Prestrelski SJ. 2000. Biopharmaceutical powders: Particle formation and formulation considerations. Curr Pharma Biotechnol 1:283-302.
5. Lee G. 2002. Spray-drying of proteins. Pharma Biotechnol 13 (Rational Design of Stable Protein Formulations):135-158.
6. Maa Y.-F, Ameri M, Chen D. 2004. Spray-coating for biopharmaceutical powder formulations: Beyond the conventional scale and its application. Pharma Res 21:515-523.
7. Jovanovic N, Bouchard A, Jiskoot W. 2004. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharma Res 21:1955-1969.
8. Maa Y-F, Nguyen P-A, Hsu CC. 1999. Protein inhalation powders: Spray drying vs spray freeze drying. Pharma Res 16:249-254.
9. Annear DI. 1970. Recoveries of bacteria after drying and heating in glutamate foams. J hygiene 68:457-459.
10. Annear DI. 1966. Recoveries of bacteria after drying in vacuo at a bath temperature of 100 degrees C. Nature 211:761.
11. Annear DI. 1956. The preservation of bacteria by drying in peptone plugs. J hygiene 54:487-508.
12. Truong-Le V. 2003. Preservation of bioactive materials by freeze dried foam. (Medimmune Vaccines, Inc., USA). Application: WO. p. 72.
13. Mattern M, Winter G, Lee G. 1997. Formulation of proteins in vacuum-dried glasses. Part 1. Improved vacuum-drying of sugars using crystallizing amino acids. Eur J Pharma Biopharma 44: 177-185.
14. Mattern M, Winter G, Lee G. 1999. Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems. Pharma Dev Technol 4:199-208.
15. Worrall EE, Litamoi JK, Ayelet G. 2000. Xerovac: An ultra rapid method for the dehydration and preservation of live attenuated Rinderpest and Peste des Petits ruminants vaccines. Vaccine 19: 834-839.
16. Hill SA, MacNaughtan W, Whitcombe MJ. 2005. The effect of thermal history on the maillard reaction in a glassy matrix. J Agri Food Chem 53: 10213-10218.
17. Abdul-Fattah A, Dellerman K, Bogner R, Pikal M. The effect of annealing on the stability of amorphous solids: Chemical stability of freeze-dried moxalactam. J Pharm Sci (in press).
18. Krishnamurthy R, Manning MC. 2002. The stability factor: Importance in formulation development. Curr Pharma Biotechnol 3:361-371.
19. Pikal MJ. 1994. Freeze-drying of proteins: Process, formulation, and stability. ACS Symposium Series, 567 (Formulation and Delivery of Proteins and Peptides):120-133.
20. Carpenter JF, Prestrelski SJ, Dong A. 1998. Application of infrared spectroscopy to development of stable lyophilized protein formulations. Eur J Pharma Biopharma 45:231-238.
21. Franks F, Hatley RHM, Mathias SF. 1991. Materials science and the production of shelf-stable biologicals. BioPharm (Duluth, MN, United States) 4:38.
22. Pikal MJ. 2004. Mechanisms of protein stabilization during freeze-drying and storage: The relative importance of thermodynamic stabilization and glassy state relaxation dynamics. Drugs Pharma Sci 137 (Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products):63-107.
23. Cicerone MT, Tellington A, Sokolov A. 2003. Substantially improved stability of biological agents in dried form: The role of glassy dynamics in preservation of biopharmaceuticals. BioProcess Int 1:36-38.
24. Yoshioka S, Aso Y, Kojima S. 2004. Temperature-and glass transition temperature-dependence of bimolecular reaction rates in lyophilized formulations described by the Adam-Gibbs-Vogel equation. J Pharma Sci 93:1062-1069.
25. Cleland J.L, Lam X, Carpenter J.F. 2001. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharma Sci 90:310-321.
26. Duddu SP, Zhang G, Dal Monte PR. 1997. The relationship between protein aggregation and molecular mobility below the glass transition temperature of lyophilized formulations containing a monoclonal antibody. Pharma Res 14:596-600.
27. Yoshioka S, Aso Y, Kojima S. 1996. Determination of molecular mobility of lyophilized bovine serum albumin and g-globulin by solid-state 1H NMR and relation to aggregation-susceptibility. Pharma Res 13:926-930.
28. Chang L, Shepherd D, Pikal MJ. 2005. Mechanism of protein stabilization by sugars during freeze-drying and storage: Native structure preservation, specific interaction, and/or immobilization in a glassy matrix? J Pharma Sci 94:1427-1444.
29. Yoshioka S, Aso Y, Miyazaki T. 2006. Negligible contribution of molecular mobility to the degradation rate of insulin lyophilized with polyvinylpyrrolidone). J Pharma Sci 95:939-943.
30. Buera MP, Rossi S, Chirife J. 1999. DSC confirmation that vitrification is not necessary for stabilization of the restriction enzyme Eco RI dried with saccharides. Biotechnology Progress 15:577-579.
31. Davidson P, Sun WQ. 2001. Effect of sucrose/raffinose mass ratios on the stability of co-lyophilized protein during storage above the Tg. Pharma Res 18:474-479.
32. Cicerone MT, Soles CL. 2004. Fast dynamics and stabilization of proteins: Binary glasses of trehalose and glycerol. Biophys J 86:3836-3845.
33. Cicerone MT, Pikal MJ, Chang L. 2005. Fast dynamics as a diagnostic for excipients in preservation of dried proteins. Am Pharma Rev 8:22, 24-27.
34. Yoshioka S, Miyazaki T, Aso Y. 2006. b-Relaxation of insulin molecule in lyophilized formulations containing trehalose or dextran as a determinant of chemical reactivity. Pharma Res 23:961-966.
35. Sane SU, Wong R, Hsu CC. 2004. Raman spectroscopic characterization of drying-induced structural changes in a therapeutic antibody: Correlating structural changes with long-term stability. J Pharma Sci 93:1005-1018.
36. Webb SD, Golledge SL, Randolph TW. 2002. Surface adsorption of recombinant human interferon-g in lyophilized and spray-lyophilized formulations. J Pharma Sci 91:1474-1487.
37. Faeldt P, Bergenstahl B. 1994. The surface composition of spray-dried protein-lactose powders. Colloids and Surfaces, A: Physicochem Eng Aspects 90:183-190.
38. Millqvist-Fureby A, Burns N, Bergenstahl B. 1999. Surface activity at the air-water interface in relation to surface composition of spray-dried milk protein-stabilized emulsions. Special Publication - Royal Soc Chem 227 (Food Emulsions and Foams):236-245.
39. Millqvist-Fureby A, Malmsten M, Bergenstahl B. 1999. Surface characterisation of freeze-dried protein/carbohydrate mixtures. Int J Pharma 191: 103-114.
40. Millqvist-Fureby A, Malmsten M, Bergenstahl B. 1999. Spray-drying of trypsin - Surface characterisation and activity preservation. Int J Pharma 188:243-253.
41. Adler M, Lee G. 1999. Stability and surface activity of lactate dehydrogenase in spray-dried trehalose. J Pharma Sci 88:199-208.
42. Adler M, Unger M, Lee G. 2000. Surface composition of spray-dried particles of bovine serum albumin/trehalose/surfactant. Pharma Res 17: 863-870.
43. Yu Z, Johnston KP, Williams RO. 2006. Spray freezing into liquid versus spray-freeze drying: Influence of atomization on protein aggregation and biological activity. Eur J Pharma Sci 27:9-18.
44. Breen ED, Curley JG, Shire SJ. 2001. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharma Res 18:1345-1353.
45. Maury M, Murphy K, Lee G. 2005. Spray-drying of proteins: Effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G. Eur J Pharma Biopharma 59: 251-261.
46. Chang L, Shepherd D, Pikal MJ. 2005. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state. J Pharma Sci 94:1445-1455.
47. Abdul-Fattah A, Pikal M, Lechuga-Ballesteros D. 2005. Composition heterogeneity effects due to variation in processing and formulation of Methionyl-human Growth Hormone, in AAPS National Biotechnology Conference. San Francisco, CA:
48. Sovani S.D, Chou E, Crofts J.D. 2001. High pressure effervescent atomization: Effect of ambient pressure on spray cone angle. Fuel 80:427-435.
49. Truong-Le V, Scherer T. 2005. High pressure spray-dry of bioactive materials. (Medimmune Vaccines, Inc., USA). Application: WO. p. 71.
50. Lide DR. 2002. Handbook of Chemistry and Physics, 83rd Edition. Boca Raton, FL: CRC Press, pp. 2664 pp.
51. Faeldt P, Bergenstahl B, Carlsson G. 1993. The surface coverage of fat on food powders analyzed by ESCA (electron spectroscopy for chemical analysis). Food Struct 12:225-234.
52. Kendrick BS, Dong A, Carpenter JF. 1996. Quantitation of the area of overlap between second-derivative amide I infrared spectra to determine the structural similarity of a protein in different states. J Pharma Sci 85:155-158.
53. DePaz RA, Dale DA, Randolph TW. 2002. Effects of drying methods and additives on the structure, function, and storage stability of subtilisin: Role of protein conformation and molecular mobility. Enzyme Microbial Technol 31:765-774.
54. Dong A, Meyer JD, Carpenter JF. 2000. Comparative Fourier transform infrared and circular dichroism spectroscopic analysis of a1-proteinase inhibitor and ovalbumin in aqueous solution. Arch Biochem Biophys 383:148-155.
55. Izutsu K-i, Aoyagi N, Kojima S. 2004. Protection of protein secondary structure by saccharides of different molecular weights during freeze-drying. Chem Pharma Bull 52:199-203.
56. Heller MC, Carpenter JF, Randolph TW. 1999. Conformational stability of lyophilized PEGylated proteins in a phase-separating system. J Pharma Sci 88:58-64.
57. Dong A, Caughey WS. 1994. Infrared methods for study of hemoglobin reactions and structures. Methods Enzymol 232 (Hemoglobins, Pt. C):139-175.
58. Prestrelski SJ, Tedeschi N, Carpenter JF. 1993. Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. Biophys J 65:661-671.
59. Liu J, Rigsbee D.R, Pikal M.J. 2002. Dynamics of pharmaceutical amorphous solids: The study of enthalpy relaxation by isothermal microcalorimetry. J Pharma Sci 91:1853-1862.
60. Kawakami K, Pikal MJ. 2005. Calorimetric investigation of the structural relaxation of amorphous materials: Evaluating validity of the methodologies. J Pharma Sci 94:948-965.
61. Meyer A, Dimeo RM, Neumann DA. 2003. The high-flux backscattering spectrometer at the NIST Center for Neutron Research. Rev Sci Instrum 74: 2759-2777.
62. Pikal MJ, Dellerman KM, Riggin RM. 1991. The effects of formulation variables on the stability of freeze-dried human growth hormone. Pharma Res 8:427-436.
63. Angell CA. 1995. Formation of glasses from liquids and biopolymers. Science (Washington, D. C.) 267: 1924-1935.
64. Carpenter JF, Izutsu K.-i, Randolph TW. 2004. Freezing- and drying-induced perturbations of protein structure and mechanisms of protein protection by stabilizing additives. Drugs Pharma Sci 137 (Freeze-Drying/ Lyophilization of Pharmaceutical and Biological Products):147-186.
65. Prestrelski SJ, Pikal KA, Arakawa T. 1995. Optimization of lyophilization conditions for recombinant human interleukin-2 by dried-state conformational analysis using Fourier-transform infrared spectroscopy. Pharma Res 12:1250-1259.
66. Lu X, Pikal MJ. 2004. Freeze-Drying of Mannitol-Trehalose-Sodium Chloride-Based Formulations: The Impact of Annealing on Dry Layer Resistance to Mass Transfer and Cake Structure. Pharma Dev Technol 9:85-95.
67. Pikal MJ, Shah S, Lang J.E. 1983. Physical chemistry of freeze-drying: Measurement of sublimation rates for frozen aqueous solutions by a microbalance technique. J Pharma Sci 72:635-650.
68. Randolph TW, Searles JA. 2002. Freezing and annealing phenomena in lyophilization: Effects upon primary drying rate, morphology, and heterogeneity. Am Pharma Rev 5:40,42,44-46.
69. Searles JA, Carpenter JF, Randolph TW. 2001. Annealing to optimize the primary drying rate, reduce freezing-induced drying rate heterogeneity, and determine Tg′ in pharmaceutical lyophilization. J Pharma Sci 90:872-887.
70. Elversson J, Millqvist-Fureby A, Elofsson U. 2003. Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying. J Pharma Sci 92:900-910.
71. Elversson J, Millqvist-Fureby A. 2005. Particle size and density in spray drying-effects of carbohydrate properties. J Pharma Sci 94:2049-2060.
72. Pikal MJ. 2002. Chemistry in solid amorphous matrices: Implication for biostabilization, in Amorphous Food and Pharmaceutical Systems. Cambridge, UK: The Royal Society of Chemistry, pp. 257-272.
73. Yoshioka S, Aso Y, Kojima S. 2002. Different molecular motions in lyophilized protein formulations as determined by laboratory and rotating frame spin-lattice relaxation times. J Pharma Sci 91:2203-2210.
74. Maa Y-F, Nguyen P-AT, Hsu S.W. 1998. Spray-drying of air-liquid interface-sensitive recombinant human growth hormone. J Pharma Sci 87:152-159.
75. Pikal MJ, Rigsbee DR. 1997. The stability of insulin in crystalline and amorphous solids: Observation of greater stability for the amorphous form. Pharma Res 14:1379-1387.
76. Yoshioka S, Aso Y, Kojima S. 2001. Usefulness of the Kohlrausch-Williams- Watts stretched exponential function to describe protein aggregation in lyophilized formulations and the temperature dependence near the glass transition temperature. Pharma Res 18:256-260.
77. Tang X, Pikal MJ. 2005. Measurement of the Kinetics of Protein Unfolding in Viscous Systems and Implications for Protein Stability in Freeze-Drying. Pharma Res 22:1176-1185.
78. Sarciaux J-M, Mansour S, Nail SL. 1999. Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying. J Pharm Sci 88:1354-1361.
79. Abdul-Fattah A, Kalonia D, Pikal M. The challenge of drying method selection for protein pharmaceuticals: Product quality implications. J Pharm Sci (in press).